TREDEGAR CORP — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that TREDEGAR CORP filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2011 | Dec 31, 2011 | $800.82M | Mar 2, 2012 |
| FY2011 | Dec 31, 2010 | $739.54M | Mar 2, 2012 |
| FY2011 | Dec 31, 2009 | $657.08M | Mar 2, 2012 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | $40.55M | Mar 16, 2020 |
| FY2019 | Sep 30, 2019 | $42.67M | Mar 16, 2020 |
| FY2019 | Jun 30, 2019 | $46.78M | Mar 16, 2020 |
| FY2019 | Mar 31, 2019 | $38.79M | Mar 16, 2020 |
| FY2019 | Dec 31, 2018 | $47.83M | Mar 16, 2020 |
| FY2019 | Sep 30, 2018 | $40.48M | Mar 16, 2020 |
| FY2019 | Jun 30, 2018 | $44.65M | Mar 16, 2020 |
| FY2019 | Mar 31, 2018 | $46.73M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $39.00M | Mar 18, 2019 |
| FY2018 | Sep 30, 2017 | $43.99M | Mar 18, 2019 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $33.48M | Mar 11, 2026 |
| FY2024 | Dec 31, 2024 | ($72.70M) | Mar 12, 2025 |
| FY2024 | Sep 30, 2024 | ($3.95M) | Mar 12, 2025 |
| FY2024 | Jun 30, 2024 | $8.79M | Mar 12, 2025 |
| FY2024 | Mar 31, 2024 | $3.29M | Mar 12, 2025 |
| FY2024 | Dec 31, 2023 | ($35.59M) | Mar 12, 2025 |
| FY2024 | Sep 30, 2023 | ($50.38M) | Mar 12, 2025 |
| FY2024 | Jun 30, 2023 | ($18.92M) | Mar 12, 2025 |
| FY2024 | Mar 31, 2023 | ($1.01M) | Mar 12, 2025 |
| FY2024 | Dec 31, 2022 | $28.46M | Mar 12, 2025 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $702.0K | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | $711.0K | Mar 11, 2026 |
| FY2025 | Dec 31, 2023 | $2.89M | Mar 11, 2026 |
| FY2024 | Dec 31, 2022 | $5.32M | Mar 12, 2025 |
| FY2023 | Dec 31, 2021 | $6.35M | Mar 15, 2024 |
| FY2022 | Dec 31, 2020 | $8.40M | Mar 16, 2023 |
| FY2019 | Dec 31, 2019 | $19.64M | Mar 16, 2020 |
| FY2019 | Dec 31, 2018 | $18.71M | Mar 16, 2020 |
| FY2019 | Dec 31, 2017 | $18.29M | Mar 16, 2020 |
| FY2018 | Dec 31, 2016 | $19.12M | Mar 18, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $79.03M | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | $72.97M | Mar 11, 2026 |
| FY2025 | Dec 31, 2023 | $65.39M | Mar 11, 2026 |
| FY2024 | Dec 31, 2022 | $69.61M | Mar 12, 2025 |
| FY2023 | Dec 31, 2021 | $74.96M | Mar 15, 2024 |
| FY2022 | Dec 31, 2020 | $84.25M | Mar 16, 2023 |
| FY2019 | Dec 31, 2019 | $94.35M | Mar 16, 2020 |
| FY2019 | Dec 31, 2018 | $85.28M | Mar 16, 2020 |
| FY2019 | Dec 31, 2017 | $83.39M | Mar 16, 2020 |
| FY2018 | Dec 31, 2016 | $73.47M | Mar 18, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $32.98M | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | $25.51M | Mar 11, 2026 |
| FY2025 | Dec 31, 2023 | $24.00M | Mar 11, 2026 |
| FY2024 | Dec 31, 2022 | ($20.84M) | Mar 12, 2025 |
| FY2023 | Dec 31, 2021 | $70.58M | Mar 15, 2024 |
| FY2022 | Dec 31, 2020 | $74.37M | Mar 16, 2023 |
| FY2019 | Dec 31, 2019 | $115.86M | Mar 16, 2020 |
| FY2019 | Dec 31, 2018 | $97.79M | Mar 16, 2020 |
| FY2019 | Dec 31, 2017 | $88.22M | Mar 16, 2020 |
| FY2018 | Dec 31, 2016 | $48.87M | Mar 18, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $17.24M | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | $14.35M | Mar 11, 2026 |
| FY2025 | Dec 31, 2023 | $26.45M | Mar 11, 2026 |
| FY2024 | Dec 31, 2022 | $36.88M | Mar 12, 2025 |
| FY2023 | Dec 31, 2021 | $27.36M | Mar 15, 2024 |
| FY2022 | Dec 31, 2020 | $23.36M | Mar 16, 2023 |
| FY2019 | Dec 31, 2019 | $50.86M | Mar 16, 2020 |
| FY2019 | Dec 31, 2018 | $40.81M | Mar 16, 2020 |
| FY2019 | Dec 31, 2017 | $44.36M | Mar 16, 2020 |
| FY2018 | Dec 31, 2016 | $45.46M | Mar 18, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $371.37M | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | $356.36M | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | $446.46M | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | $542.09M | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | $523.58M | Mar 16, 2023 |
| FY2019 | Dec 31, 2019 | $712.67M | Mar 16, 2020 |
| FY2019 | Dec 31, 2018 | $707.37M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $755.74M | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | $651.16M | Feb 22, 2018 |
| FY2016 | Dec 31, 2015 | $623.26M | Feb 22, 2017 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $154.82M | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | $175.39M | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | $290.81M | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | $340.33M | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | $338.86M | Mar 16, 2023 |
| FY2019 | Dec 31, 2019 | $335.92M | Mar 16, 2020 |
| FY2019 | Dec 31, 2018 | $352.52M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $411.96M | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | $340.38M | Feb 22, 2018 |
| FY2016 | Dec 31, 2015 | $350.51M | Feb 22, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $216.55M | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | $180.97M | Mar 11, 2026 |
| FY2025 | Dec 31, 2023 | $155.65M | Mar 11, 2026 |
| FY2025 | Dec 31, 2022 | $201.76M | Mar 11, 2026 |
| FY2024 | Dec 31, 2021 | $184.72M | Mar 12, 2025 |
| FY2023 | Dec 31, 2020 | $109.06M | Mar 15, 2024 |
| FY2022 | Dec 31, 2019 | $376.75M | Mar 16, 2023 |
| FY2019 | Dec 31, 2018 | $354.86M | Mar 16, 2020 |
| FY2019 | Dec 31, 2017 | $343.78M | Mar 16, 2020 |
| FY2019 | Dec 31, 2016 | $310.78M | Mar 16, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $22.45M | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | $22.45M | Mar 11, 2026 |
| FY2025 | Dec 31, 2023 | $35.72M | Mar 11, 2026 |
| FY2024 | Dec 31, 2022 | $70.61M | Mar 12, 2025 |
| FY2023 | Dec 31, 2021 | $70.61M | Mar 15, 2024 |
| FY2022 | Dec 31, 2020 | $67.71M | Mar 16, 2023 |
| FY2019 | Dec 31, 2019 | $81.40M | Mar 16, 2020 |
| FY2019 | Dec 31, 2018 | $81.40M | Mar 16, 2020 |
| FY2019 | Dec 31, 2017 | $128.21M | Mar 16, 2020 |
| FY2018 | Dec 31, 2016 | $117.82M | Mar 18, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $146.89M | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | $113.41M | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | $177.98M | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | $292.72M | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | $281.19M | Mar 16, 2023 |
| FY2019 | Dec 31, 2019 | $530.48M | Mar 16, 2020 |
| FY2019 | Dec 31, 2018 | $497.51M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $487.23M | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | $463.51M | Feb 22, 2018 |
| FY2016 | Dec 31, 2015 | $453.47M | Feb 22, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.73M | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | $7.06M | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | $9.66M | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | $19.23M | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | $30.52M | Mar 16, 2023 |
| FY2019 | Dec 31, 2019 | $31.42M | Mar 16, 2020 |
| FY2019 | Dec 31, 2018 | $34.40M | Mar 16, 2020 |
| FY2019 | Dec 31, 2017 | $36.49M | Mar 16, 2020 |
| FY2019 | Dec 31, 2016 | $29.51M | Mar 16, 2020 |
| FY2018 | Dec 31, 2015 | $44.16M | Mar 18, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $137.00M | Mar 16, 2023 |
| FY2019 | Dec 31, 2019 | $42.00M | Mar 16, 2020 |
| FY2018 | Dec 31, 2018 | $101.50M | Mar 18, 2019 |
| FY2017 | Dec 31, 2017 | $152.00M | Feb 22, 2018 |
| FY2016 | Dec 31, 2016 | $95.00M | Feb 22, 2017 |
| FY2015 | Dec 31, 2015 | $104.00M | Mar 9, 2016 |
| FY2014 | Dec 31, 2014 | $137.25M | Mar 2, 2015 |
| FY2013 | Dec 31, 2013 | $139.00M | Feb 28, 2014 |
| FY2012 | Dec 31, 2012 | $128.00M | Mar 1, 2013 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 11, 2026 |
| FY2024 | Dec 31, 2024 | (2) | Mar 12, 2025 |
| FY2024 | Sep 30, 2024 | 0 | Mar 12, 2025 |
| FY2024 | Jun 30, 2024 | 0 | Mar 12, 2025 |
| FY2024 | Mar 31, 2024 | 0 | Mar 12, 2025 |
| FY2024 | Dec 31, 2023 | (1) | Mar 12, 2025 |
| FY2024 | Sep 30, 2023 | (1) | Mar 12, 2025 |
| FY2024 | Jun 30, 2023 | 0 | Mar 12, 2025 |
| FY2024 | Mar 31, 2023 | 0 | Mar 12, 2025 |
| FY2024 | Dec 31, 2022 | 0 | Mar 12, 2025 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 11, 2026 |
| FY2024 | Dec 31, 2024 | (2) | Mar 12, 2025 |
| FY2024 | Sep 30, 2024 | 0 | Mar 12, 2025 |
| FY2024 | Jun 30, 2024 | 0 | Mar 12, 2025 |
| FY2024 | Mar 31, 2024 | 0 | Mar 12, 2025 |
| FY2024 | Dec 31, 2023 | (1) | Mar 12, 2025 |
| FY2024 | Sep 30, 2023 | (1) | Mar 12, 2025 |
| FY2024 | Jun 30, 2023 | 0 | Mar 12, 2025 |
| FY2024 | Mar 31, 2023 | 0 | Mar 12, 2025 |
| FY2024 | Dec 31, 2022 | 0 | Mar 12, 2025 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 34.74M | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | 34.66M | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | 34.41M | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | 34.00M | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | 33.74M | Mar 16, 2023 |
| FY2019 | Dec 31, 2019 | 33.37M | Mar 16, 2020 |
| FY2019 | Dec 31, 2018 | 33.18M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | 33.02M | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | 32.93M | Feb 22, 2018 |
| FY2016 | Dec 31, 2015 | 32.68M | Feb 22, 2017 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0 | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | $0 | Mar 11, 2026 |
| FY2025 | Dec 31, 2023 | $8.88M | Mar 11, 2026 |
| FY2024 | Dec 31, 2022 | $16.97M | Mar 12, 2025 |
| FY2023 | Dec 31, 2021 | $16.17M | Mar 15, 2024 |
| FY2022 | Dec 31, 2020 | $216.05M | Mar 16, 2023 |
| FY2019 | Dec 31, 2019 | $15.33M | Mar 16, 2020 |
| FY2019 | Dec 31, 2018 | $14.59M | Mar 16, 2020 |
| FY2019 | Dec 31, 2017 | $14.53M | Mar 16, 2020 |
| FY2018 | Dec 31, 2016 | $14.46M | Mar 18, 2019 |